Vandana Singh

Vandana Singh

Benzinga Editor

About
Vandana Singh, MBA Finance is an Editor of the Benzinga Breaking News. Vandana has been covering the healthcare sector for over 10 years, including providing support services to renowned investment banks.
MacroGenics Gets Downgraded Following Disappointing Prostate Cancer Trial Results: 'We Were Surprised By Reported Deaths'
Despite MacroGenics' clinical activity, unexpected adverse events raise concerns. Analysts adjust ratings and price targets.
From Hype To Reality, AI Reshapes Pharmaceutical Industry Across Drug Discovery To Marketing - Stocks To Watch
Unlock the potential of AI in pharmaceuticals. With AI's help, the pharma industry could see $60B-$110B in annual economic value. Dive into the future of drug discovery and clinical development with leading players like Google, Nvidia, and Microsoft.
Fertility Solutions-Focused Progyny Stock Sinks After Soft Guidance; Analyst Says 'Can No Longer Underwrite Sustained Healthy Growth In Forecasts'
Progyny reported first-quarter sales of $278.1 million, slightly below expectations due to increased clients and covered lives. KeyBanc Capital Markets downgraded Progyny from Overweight to Sector Weight, citing concerns about revenue visibility and customer behavior.
MacroGenics Shares Tumble After Reporting Adverse Events, Multiple Deaths In Cancer Drug Trial
Latest interim data from TAMARACK Phase 2 study by MacroGenics unveils insights into vobramitamab duocarmazine targeting B7-H3 in metastatic prostate cancer. Despite responses, notable safety concerns reported.
What's Going On With Medical Therapeutic Firm Aethlon Medical On Friday?
Aethlon Medical unveils results in removing extracellular vesicles (EVs) from plasma. Preclinical evidence supports upcoming phase 1 trials for solid tumor patients undergoing anti-PD-1 monotherapy.
FDA Delays 'Important' Moderna Vaccine Review: William Blair Says 2025 Growth, '2026 Breakeven Story' Depends On It
FDA update: Moderna's BLA for mRNA-1345, RSV vaccine, may face delay past May 12 deadline. But no safety concerns reported.
Some Breather For Novavax's COVID-19 Vaccine, Inks Multibillion-Dollar Deal With Sanofi And Erases Doubts About Its Going Concern
Novavax strikes co-exclusive licensing deal with Sanofi (SNY) for COVID-19 and flu-COVID-19 vaccines. Terms include upfront payment of $500M, milestone opportunities, and revenue guidance update.
Analysts' Varied Perspectives On CytomX's CX-904 Cancer Study: Safety Profile But Caution in Pancreatic Cancer
Initial data from CytomX Therapeutics' CX-904 Phase 1a study shows safety and anti-cancer activity in heavily pretreated patients with advanced metastatic solid tumors. Reductions observed, especially in pancreatic cancer, with stable disease maintained.
Change Healthcare Cyberattack: GoodRx Expects Low Single Digit Million-Dollar Impact In 2024
GoodRx's Q1 earnings: $0.08 EPS, sales hit $197.88 million, beating expectations fueled by prescription transactions and pharma solutions. Q2 forecast: ~$200 million revenue, optimistic 2024 outlook.
Weak Sales From Lipitor, Norvasc Hurt Viatris' Q1 Earnings, Lowers Annual Forecast
Viatris reports Q1 EPS in line with consensus at $0.67, with sales slightly missing expectations at $3.66 billion. Strong growth in Emerging Markets and Europe offset by challenges in North America. Guidance adjusted slightly downward for 2024.
What's Going On With Dermatitis-Focused RAPT Therapeutics Stock On Thursday?
RAPT Therapeutics closes Phase 2 trials for zelnecirnon in atopic dermatitis & asthma following FDA clinical hold due to liver failure.
Japan's Takeda Pharma Outlines $900M Overhaul To Boost Growth, As 2023 Profit Fall Over 50%
Takeda Pharmaceutical (NYSE: TAK) reveals fiscal year 2023 results & restructuring plan. Revenue up 5.9%, net profit down 54.6%. Expecting operating profit of 225 billion yen in 2024.
EXCLUSIVE: Alzamend Neuro To Raise Up To $25M Via Private Placement Of Preferred Shares
Alzamend Neuro seals $500,000 Series A Convertible Preferred Stock deal with an investor. Plans to raise up to $25 million for clinical trials and working capital.
Italy Based Stevanato Reports Mixed Q1 Earnings, Revises Annual Guidance On Temporary Destocking
Stevanato Group reports Q1 earnings of 236.0 million euros, down 1% Y/Y. Sales declined due to vial destocking amid pandemic effects. High-value solutions revenue up to 37% driven by syringe demand. Updated FY24 guidance reflects cautious outlook.
Buy Definitive Healthcare Stock On Weakness, Analyst Says As Revised Outlook Appears Achievable
Definitive Healthcare reports Q1 adjusted EPS of $0.08, sales at $63.48M, and adjusted EBITDA of $20 million. Q2 revenue guidance: $62–$63.5 million. FY 2024 revenue outlook: $255–$261 million.
Google DeepMind Develops Latest AI Model To Aid Scientists In Fighting Disease
Google DeepMind reveals its AlphaFold 3, which specializes in molecular predictions for proteins, DNA, RNA, and drug molecules.
Orthopedic Devices Maker Treace Medical Concepts' Gloomy Forecast Cast Concerns Over Long-Term Viability
Treace Medical Concepts reports Q1 EPS loss of $(0.30), sales hit $51.11 million, up 21%. Surge in procedure kits sold due to expanded surgeon base and product mix shift. FY24 sales guidance adjusted to $201M-$211M. Analysts downgrade, citing competitive challenges.
Pfizer Agrees To Settle Over 10,000 Lawsuits About Cancer Risks Associated With Discontinued Heartburn Drug Zantac
Pfizer settles 10,000 Zantac lawsuits over cancer risks, but challenges remain. Details undisclosed. Sanofi's $100 million+ agreement also noted. Legal battles ongoing.
Why Is New York Times Stock Trading Higher On Wednesday?
New York Times' digital subscribers hit 9.91 million, growing by 210K in Q1. Sales reached $594M, up 5.9% Y/Y. Digital ARPU rose to $9.21. CEO Meredith Kopit Levien emphasizes a strong start in 2024. Guidance predicts subscription revenues up by 6%-8% in Q2.
Elanco Animal Health's Q1 Earnings Show Improved Base Business, Analyst Highlights Slightly Delayed But Encouraging Pipeline
Elanco Animal Health (NYSE: ELAN) reports Q1 results: adjusted EPS $0.34 (-26% Y/Y), sales $1.21B (-4% Y/Y). 2024 guidance: EPS $0.88-$0.96, revenue $4.46-$4.52 billion.